| 常用名 | YHO-13351 | CAS号 | 1346753-00-1 |
|---|---|---|---|
| 价格 | ¥1332.0/5mg ¥需询单/1g ¥需询单/1g ¥需询单/1g | 纯度 | 98.0% |
| 备货期 | 1天 | 库存 | 现货 |
| 产品网页 | http://www.aladdin-e.com/zh_cn/Y302452.html | ||
| 产品详情(用途,包装等)
用途: YHO-13351 is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP.IC50 value:Target: BCRP inhibitorin vitro: YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38–resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but had little effect in the parental cells. In addition, YHO-13177 potentiated the cytotoxicity of SN-38 in human lung cancer NCI-H460 and NCI-H23, myeloma RPMI-8226, and pancreatic cancer AsPC-1 cells that intrinsically expressed BCRP. In contrast, it had no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells and multidrug resistance-related protein 1–mediated doxorubicin resistance in MRP1-transfected human epidermoid cancer KB-3-1 cells. YHO-13177 increased the intracellular accumulation of Hoechst 33342, a substrate of BCRP, at 30 minutes and partially suppressed the expression of BCRP protein at more than 24 hours after its treatment in both HCT116/BCRP and A549/SN4 cells [1].in vivo: In mice, YHO-13351 was rapidly converted into YHO-13177 after its oral or intravenous administration. Coadministration of irinotecan with YHO-13351 significantly increased the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas irinotecan alone had little effect in these tumor models [1]. 物理化学性质: CAS号:1346753-00-1 常用中文名:YHO-13351 常用英文名:YHO-13351 分子式:C27H37N3O7S2 分子量:579.729 密度:N/A 沸点:N/A 熔点:N/A 闪点:N/A 储存条件:2-8℃ |